Hepatitis B "drug bully" price reduction of 90%! Industry calls new drug research and development worth looking forward to

[China Pharmaceutical network industry trends] on December 6, the national "4 + 7" volume procurement pre bid results were announced From various situations of negotiation, "price reduction" has become the key word It is understood that entecavir is an oral drug for the treatment of hepatitis B virus infection It has an inhibitory effect on hepatitis B virus (HBV) polymerase At present, it is mainly used for antiviral treatment of hepatitis B, and also for the treatment of children with chronic HBV infection and compensatory liver disease between 2 and 18 years old The drug has the characteristics of rapid onset, strong resistance to hepatitis B virus and low resistance, and is the first-line antiviral treatment for chronic hepatitis B patients Hepatitis B virus (HBV) infection is an important cause of liver cirrhosis and liver cancer According to the World Health Organization, about 2 billion people have been infected with hepatitis B virus in the world, 350 million of them are chronic hepatitis B patients, and about 1 million people die of liver failure caused by hepatitis B every year China is one of the high incidence areas of hepatitis B According to statistics, the incidence rate of hepatitis B is increasing in China, and there is no high cure rate in the field of hepatitis B This makes the treatment of hepatitis B virus a long term and the market capacity of hepatitis B drug consumption is very large The results of the volume purchase announced that the price of hepatitis B "drug bully" was reduced by 90%, which can not help but make patients happy It is urgent to strengthen the innovative research and development of hepatitis B drugs Industry said that although the cure for hepatitis B has not been found, but the world is constantly tackling problems, explore the treatment path of hepatitis B As a recent article in science focused on the treatment of hepatitis B pointed out, the current candidate drugs have targeted almost every point in the complex life cycle of HBV "At present, the international research on the treatment of hepatitis B has taken a big step In addition to catching up, the research on the contribution of traditional Chinese medicine to the treatment of hepatitis B may provide a new way for Chinese researchers." Some experts said According to the industry, traditional Chinese medicine has become an important field of liver disease treatment, and has made important breakthroughs in recent years Especially for drug-induced liver injury, Hugan tablet is a leap of traditional Chinese medicine in the field of liver disease treatment, and also a model of modernization of traditional Chinese medicine, which has epoch-making significance Therefore, experts call for: "drug-induced liver injury has a serious harm, should cause the full attention of the whole society, scientific prevention, timely standardized treatment, reduce its risk and harm to a low level." China is one of the countries with outstanding hepatitis B problem in the world In order to ensure that the majority of patients can use good drugs and cheap drugs, China still needs a lot of work to do In addition to reducing the price of generic drugs and increasing the research of traditional Chinese medicine, China needs to continue to carry out technological innovation and develop more good drugs suitable for hepatitis B virus It is understood that with the growth of China's medical science and technology, hepatitis B is no longer so terrible, but there is still a lack of effective cure means, all we can do is to stabilize the development of the disease However, it has also been pointed out that a group of new domestic enterprises and research institutions with strong scientific research strength have made considerable progress in the research and development of new hepatitis B drugs, and the prospect is worth looking forward to For example, recently, heponofovir, a class 1.1 liver targeted anti hepatitis therapeutic drug jointly declared by Xi'an Xintong Pharmaceutical Research Co., Ltd and Guangzhou Qifang Pharmaceutical Co., Ltd., obtained the notice of clinical trial issued by CFDA, and heponofovir (HTS) was approved by the state and officially entered the stage of clinical research The product is the second generation of hepatitis B targeted new drug developed by Xi'an Xintong Pharmaceutical Research Co., Ltd on the basis of its national "13th five year plan" major new drug creation "hepdirect" technology platform with independent intellectual property rights According to the relevant staff, compared with tenofovir, the dosage of heptenofovir is smaller, there is no obvious rebound of the virus two weeks after the discontinuation of the drug, which is expected to be developed into a low toxicity long-term oral preparation, providing a new drug selection for patients with hepatitis B, and has a broad application prospect